0001209191-22-013160.txt : 20220225
0001209191-22-013160.hdr.sgml : 20220225
20220225161819
ACCESSION NUMBER: 0001209191-22-013160
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220223
FILED AS OF DATE: 20220225
DATE AS OF CHANGE: 20220225
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Alam Kamran
CENTRAL INDEX KEY: 0001793412
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39536
FILM NUMBER: 22680262
MAIL ADDRESS:
STREET 1: 350 FIFTH AVENUE, SUITE 7530
CITY: NEW YORK
STATE: NY
ZIP: 10118
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Taysha Gene Therapies, Inc.
CENTRAL INDEX KEY: 0001806310
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 843199512
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
BUSINESS PHONE: (214) 612-0000
MAIL ADDRESS:
STREET 1: 3000 PEGASUS PARK DRIVE
STREET 2: SUITE 1430
CITY: DALLAS
STATE: TX
ZIP: 75247
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-23
0
0001806310
Taysha Gene Therapies, Inc.
TSHA
0001793412
Alam Kamran
C/O TAYSHA GENE THERAPIES, INC.
3000 PEGASUS PARK DRIVE, STE 1430
DALLAS
TX
75247
0
1
0
0
Chief Financial Officer
Employee Stock Option (right to buy)
5.96
2022-02-23
4
A
0
80000
0.00
A
2032-02-23
Common Stock
80000
80000
D
25% of the total number of shares underlying the option shall vest and become exercisable on February 23, 2023 and the remainder shall vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.
/s/ Kamran Alam
2022-02-25